

Clinical applications of nanotechnologies in the field of cancer

January 28 and 29, 2010 - Montpellier, France

ADVANCED PROGRAMME

Thursday, January 28, 2010

9h15

Welcome & Opening

Objectives of seminar and context of nanomedicine applied to clinical practice

Peter PAUWELS, Evelyne CREMER, Josep SAMITIER

9h30 - 10h00

Research on nanomedicine applied to cancer in Europe and European Technology Platform: Spanish and French technology platforms

Josep SAMITIER, François BERGER

10h00 - 11h30

SESSION 1: Presentation of nano research activities: IBEC/Biopol L'H-Barcelona, Cancéropôle Grand Sud-Ouest and Cancéropôle Lyon Auvergne Rhône-Alpes

10h00 - 10h20

Institut de Bioenginyeria de Catalunya (IBEC) / Biopol L'H
Josep SAMITIER

10h20 - 10h40

Canceropole Grand-Sud-Ouest & Fondation InnaBiosanté
Lionel HAVION

10h40 - 11h00

Canceropole Lyon Auvergne Rhône-Alpes
François BERGER, Marc JANIER

11h00 - 11h30

Break and Posters

11h30 - 16h00

SESSION 2: Transfer of nanotechnology to clinical applications related to cancer

Chair/Moderators: Josep SAMITIER (IBEC, Barcelona) and François BERGER (INSERM – UJF, Grenoble)

- 11h30 - 12h00 Ultrasound triggered, image guided, drug delivery
Chrit MOONEN, UMR5231 CNRS, University Victor Segalen, Bordeaux
- 12h00 - 12h30 *In vitro* diagnostics: nanobioanalytical platforms
Pilar MARCO, IBEC/IQAC-CSIC, Barcelona
- 12h30-12h50 Optical imaging and cancer: from mice to man
Jean-Luc COLL, INSERM U823 - Université Joseph Fourier, Grenoble

12h50-14h20 **Lunch and posters**

- 14h20-14h40 A new platform of bio-inspired nanomedicines in oncology
Jean-Pierre BENOIT, INSERM U646, Université d'Angers
- 14h40-15h00 Presentation Title TBD
Neil DESAI, Senior VP Research & Development, Abraxis Biosciences
- 15h00 - 15h30 **Round Table I:**
What are the hot key-issues on the transfer of nanotechnology to clinical applications? How can nanomedicine contribute at the theragnostic level? Key-issues for oncospecialists. What basic research can bring to clinicians, the added value and technological limits.
Josep SAMITIER (Barcelona) and François BERGER (Grenoble)

15h30 - 16h00 **Break and Posters**

16h00 - 19h30

SESSION 3: Ethics and regulatory issues related to nanotechnologies in the field of cancer

Chair/Moderators: Simó Schwartz Jr (Catalunya) and Dominique MASSET (AFSSAPS, Paris)

- 16h00 - 16h30 A philosophical perspective on nanotechnology
Bernadette BENSUADE VINCENT, CNRS – Université Paris 10
- 16h30 - 17h00 Toxicology assays and protocols in nanomedicine
Simó SCHWARTZ Jr., CIBBIM-Hospital Vall d Hebron, Barcelona
- 17h00 - 17h20 Impact of nanotechnologies on patients: questions for ethics
Marie CHARAVEL, Université Pierre Mendès France, Grenoble
- 17h20 - 17h50 Evaluation agencies
Role in the introduction of new technologies
Marta AYMERICH, Facultat de Medicina, Universitat de Girona
Perception and risk evaluation of health products using nanotechnologies
Dominique MASSET, AFSSAPS, Paris
- 17h50 - 18h20 **Round Table II:**
Legal and regulatory framework: Spanish and French position
Marta AYMERICH (Girona), Dominique MASSET (Paris) and Jacques DESCOTES (Lyon)

18h20 - 19h20 **Appetizers and Posters**
19h30 - 22h30 **Dinner**

Friday, January 29, 2010

8h30 - 12h15

SESSION 4: Proof of concept of clinical applications in oncology

Chair/Moderators: Gabriel CAPELLA (ICO/IDIBELL, Barcelona) and Gilles DIVITA (Centre de Recherche de Biochimie Macromoléculaire, Université Montpellier, CNRS, Montpellier)

- 8h30 – 9h00 Early diagnosis in prostate cancer by means of a bionanoelectronic “nose”
Jaume RAVENTOS, IRVH, Hospital Vall d’Hebron, Barcelona
- 9h00 - 9h30 Nano-fingerprinting as a new device for theragnostic medicine applied to glioblastoma
François BERGER, INSERM U836, Université Joseph Fourier, Grenoble
- 9h30 - 10h00 Peptide-based nano-particles for targeted delivery of therapeutic siRNA
Gilles DIVITA, Centre de Recherche de Biochimie Macromoléculaire, Université Montpellier, CNRS, Montpellier

10h00 - 10h30 **Break and Posters**

- 10h30 - 11h00 Multimodality imaging in oncology utilizing targeted drug delivery systems
Kalevi KAIREMO, University of Helsinki/ South Karelia Central Hospital, Finland
- 11h00-11h30 Pancreatic cancer gene therapy: non viral gene delivery
Eric PEROUZEL, Cayla Invivogen, Toulouse
- 11h30 - 12h15 **Round Table III:**
How to go further? Clinicians addressing their practice in oncology. Examples with proof of concept. Perspectives and Follow-up.
Gabriel CAPELLA (Barcelona) and Gilles DIVITA (Montpellier)
- 12h15 - 12h30 **Closing remarks**
Institut de Bioenginyeria de Catalunya (IBEC)
Cancéropôle Grand-Sud-Ouest & Fondation InnaBiosanté
Cancéropôle Lyon Auvergne Rhône-Alpes

12h30 - 14h30 **Lunch**



SCIENTIFIC COMMITTEE:

Barcelona: Gabriel CAPELLÀ (IDIBELL), Josep RAMON GERMÀ (Head of medical Oncology - ICO), Josep SAMITIER (IBEC- Barcelona University), Simó SCHWARTZ Jr (Hospital Vall d'Hebron)

Cancéropôle GSO: Evelyne CREMER, Lionel HAVION (InnaBioSanté Foundation)

Cancéropôle CLARA: François BERGER (UJF), Marc JANIER (HCL), Peter PAUWELS

ORGANISING COMMITTEE:

Barcelona: Arantxa SANZ (IBEC)

Cancéropôle GSO: Evelyne CREMER, Charlotte FARGES, Lionel HAVION (InnaBioSanté Foundation), Karine MARENDZIAK

Cancéropôle CLARA: Leticia LOBO LUPPI, Peter PAUWELS

With the collaboration of

